MIND Institute, University of California Davis Medical Center, Sacramento, California, USA.
Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, California, USA.
Mov Disord. 2018 Apr;33(4):628-636. doi: 10.1002/mds.27314. Epub 2018 Feb 1.
Fragile X premutation carriers are at increased risk for fragile X-associated tremor ataxia syndrome (FXTAS), but to date we know little about prediction of onset and rate of progression and even less about treatment of this neurodegenerative disease. Thus, the longitudinal study of carriers, and the identification of potential biomarkers and prodromal states, is essential. Here we present results of baseline assessments from an ongoing longitudinal project.
The cohort consisted of 73 men, 48 with the fragile X mental retardation 1 (FMR1) premutation (55-200 cytosine-cytosine-guanine or CGG repeats) and 25 well-matched controls (< 40 repeats) aged between 40 and 75 years. At enrollment, none met criteria for FXTAS or had any clinically significant tremor or ataxia by blinded neurological examination. The battery consisted of measures of visual memory, spatial working memory, response inhibition, motor speed and control, planning and problem solving, sustained attention, and a standardized movement disorder evaluation.
Contrary to expectations, there were no significant differences between premutation carriers and controls on any measure of executive function. However, the premutation carriers had significantly longer manual movement and reaction times than controls, and the significant interaction between CGG repeat and age revealed the slowest movement times among older carriers with higher CGG repeat alleles. A subset of premutation carriers had marginally lower scores on the ataxia evaluation, and they performed no differently from controls on the parkinsonism assessment.
Early-developing cerebellar or fronto-motor tract white matter changes, previously documented in MRI studies, may underlie motor slowing that occurs before clinically observable neurological symptoms associated with FXTAS. © 2018 International Parkinson and Movement Disorder Society.
脆性 X 前突变携带者发生脆性 X 相关震颤共济失调综合征(FXTAS)的风险增加,但迄今为止,我们对发病预测和进展速度知之甚少,对这种神经退行性疾病的治疗更是了解甚少。因此,对携带者进行纵向研究,以及确定潜在的生物标志物和前驱状态,是至关重要的。本文介绍了正在进行的纵向研究的基线评估结果。
该队列包括 73 名男性,其中 48 名携带脆性 X 智力低下 1 型(FMR1)前突变(55-200 个胞嘧啶-胞嘧啶-鸟嘌呤或 CGG 重复),25 名年龄在 40 至 75 岁之间、与前突变携带者相匹配的对照组(<40 个重复)。入组时,所有患者均未达到 FXTAS 的诊断标准,也未通过盲法神经学检查发现任何有临床意义的震颤或共济失调。测试电池包括视觉记忆、空间工作记忆、反应抑制、运动速度和控制、计划和解决问题、持续注意力以及标准化运动障碍评估。
与预期相反,在前突变携带者和对照组之间,执行功能的任何测量指标均无显著差异。然而,前突变携带者的手部运动和反应时间明显长于对照组,并且 CGG 重复和年龄之间的显著交互作用表明,高龄、CGG 重复等位基因较高的前突变携带者的运动时间最慢。一部分前突变携带者的共济失调评估得分略低,他们在帕金森病评估中与对照组的表现无差异。
先前在 MRI 研究中记录的小脑或额-运动束白质的早期改变可能是导致 FXTAS 相关临床可见神经症状之前出现运动迟缓的原因。© 2018 国际帕金森病和运动障碍学会。